{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:05Z","timestamp":1786982765594,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100012352","name":"Universit\u00e0 degli Studi di Milano","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s40266-021-00852-8","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T05:20:39Z","timestamp":1618464039000},"page":"481-491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and Safety of the Association of Nimodipine and Choline Alphoscerate in the Treatment of Cognitive Impairment in Patients with Cerebral Small Vessel Disease. The CONIVaD Trial"],"prefix":"10.1007","volume":"38","clinical-trial-number":[{"clinical-trial-number":"nct03228498","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Emilia","family":"Salvadori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Poggesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Donnini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Rinnoci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Chiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Squitieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Tudisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Fierini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Melone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pescini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7357-8530","authenticated-orcid":false,"given":"Leonardo","family":"Pantoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,15]]},"reference":[{"issue":"2","key":"852_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/s1474-4422(03)00305-3","volume":"2","author":"JT O'Brien","year":"2003","unstructured":"O\u2019Brien JT, Erkinjuntti T, Reisberg B, et al. Vascular cognitive impairment. Lancet Neurol. 2003;2(2):89\u201398. https:\/\/doi.org\/10.1016\/s1474-4422(03)00305-3.","journal-title":"Lancet Neurol."},{"issue":"7","key":"852_CR2","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S1474-4422(10)70104-6","volume":"9","author":"L Pantoni","year":"2010","unstructured":"Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9(7):689\u2013701. https:\/\/doi.org\/10.1016\/S1474-4422(10)70104-6.","journal-title":"Lancet Neurol."},{"issue":"8","key":"852_CR3","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S1474-4422(13)70124-8","volume":"12","author":"JM Wardlaw","year":"2013","unstructured":"Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822\u201338. https:\/\/doi.org\/10.1016\/S1474-4422(13)70124-8.","journal-title":"Lancet Neurol."},{"issue":"1\u20132","key":"852_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jns.2004.09.014","volume":"226","author":"L Pantoni","year":"2004","unstructured":"Pantoni L. Treatment of vascular dementia: evidence from trials with non-cholinergic drugs. J Neurol Sci. 2004;226(1\u20132):67\u201370. https:\/\/doi.org\/10.1016\/j.jns.2004.09.014.","journal-title":"J Neurol Sci."},{"issue":"5","key":"852_CR5","doi-asserted-by":"publisher","first-page":"e005568","DOI":"10.1161\/JAHA.117.005568","volume":"6","author":"EE Smith","year":"2017","unstructured":"Smith EE, Cieslak A, Barber P, et al. Therapeutic strategies and drug development for vascular cognitive impairment. J Am Heart Assoc. 2017;6(5):e005568. https:\/\/doi.org\/10.1161\/JAHA.117.005568.","journal-title":"J Am Heart Assoc."},{"issue":"Pt 12","key":"852_CR6","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1093\/brain\/121.12.2249","volume":"121","author":"NR Selden","year":"1998","unstructured":"Selden NR, Gitelman DR, Salamon-Murayama N, Parrish TB, Mesulam MM. Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain. 1998;121(Pt 12):2249\u201357. https:\/\/doi.org\/10.1093\/brain\/121.12.2249.","journal-title":"Brain"},{"issue":"4","key":"852_CR7","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1212\/01.wnl.0000078943.50032.fc","volume":"61","author":"D Wilkinson","year":"2003","unstructured":"Wilkinson D, Doody R, Helme R, et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. 2003;61(4):479\u201386. https:\/\/doi.org\/10.1212\/01.wnl.0000078943.50032.fc.","journal-title":"Neurology"},{"issue":"10","key":"852_CR8","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1161\/01.STR.0000091396.95360.E1","volume":"34","author":"S Black","year":"2003","unstructured":"Black S, Rom\u00e1n GC, Geldmacher DS, et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke. 2003;34(10):2323\u201330. https:\/\/doi.org\/10.1161\/01.STR.0000091396.95360.E1.","journal-title":"Stroke"},{"issue":"4","key":"852_CR9","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/S1474-4422(08)70046-2","volume":"7","author":"M Dichgans","year":"2008","unstructured":"Dichgans M, Markus HS, Salloway S, et al. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol. 2008;7(4):310\u20138. https:\/\/doi.org\/10.1016\/S1474-4422(08)70046-2.","journal-title":"Lancet Neurol."},{"issue":"9314","key":"852_CR10","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S0140-6736(02)08267-3","volume":"359","author":"T Erkinjuntti","year":"2002","unstructured":"Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer\u2019s disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002;359(9314):1283\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(02)08267-3.","journal-title":"Lancet"},{"issue":"5","key":"852_CR11","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1212\/01.wnl.0000266625.31615.f6","volume":"69","author":"AP Auchus","year":"2007","unstructured":"Auchus AP, Brashear HR, Salloway S, et al. Galantamine treatment of vascular dementia: a randomized trial. Neurology. 2007;69(5):448\u201358. https:\/\/doi.org\/10.1212\/01.wnl.0000266625.31615.f6.","journal-title":"Neurology"},{"issue":"9","key":"852_CR12","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1185\/03007990802328142","volume":"24","author":"C Ballard","year":"2008","unstructured":"Ballard C, Sauter M, Scheltens P, et al. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Curr Med Res Opin. 2008;24(9):2561\u201374. https:\/\/doi.org\/10.1185\/03007990802328142.","journal-title":"Curr Med Res Opin."},{"issue":"4","key":"852_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/j.1600-0404.2009.01263.x","volume":"121","author":"K Narasimhalu","year":"2010","unstructured":"Narasimhalu K, Effendy S, Sim CH, et al. A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease. Acta Neurol Scand. 2010;121(4):217\u201324. https:\/\/doi.org\/10.1111\/j.1600-0404.2009.01263.x.","journal-title":"Acta Neurol Scand."},{"issue":"7","key":"852_CR14","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1161\/01.str.0000020094.08790.49","volume":"33","author":"JM Orgogozo","year":"2002","unstructured":"Orgogozo JM, Rigaud AS, St\u00f6ffler A, M\u00f6bius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002;33(7):1834\u20139. https:\/\/doi.org\/10.1161\/01.str.0000020094.08790.49.","journal-title":"Stroke"},{"issue":"6","key":"852_CR15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/00004850-200211000-00005","volume":"17","author":"G Wilcock","year":"2002","unstructured":"Wilcock G, M\u00f6bius HJ, St\u00f6ffler A, MMM 500 group. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002;17(6):297\u2013305. https:\/\/doi.org\/10.1097\/00004850-200211000-00005.","journal-title":"Int Clin Psychopharmacol."},{"issue":"9","key":"852_CR16","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S1474-4422(07)70195-3","volume":"6","author":"H Kavirajan","year":"2007","unstructured":"Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 2007;6(9):782\u201392. https:\/\/doi.org\/10.1016\/S1474-4422(07)70195-3.","journal-title":"Lancet Neurol."},{"issue":"9","key":"852_CR17","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1161\/STR.0b013e3182299496","volume":"42","author":"PB Gorelick","year":"2011","unstructured":"Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2011;42(9):2672\u2013713. https:\/\/doi.org\/10.1161\/STR.0b013e3182299496.","journal-title":"Stroke"},{"issue":"2","key":"852_CR18","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1159\/000346602","volume":"35","author":"J Alvarez-Sab\u00edn","year":"2013","unstructured":"Alvarez-Sab\u00edn J, Ortega G, Jacas C, et al. Long-term treatment with citicoline may improve poststroke vascular cognitive impairment. Cerebrovasc Dis. 2013;35(2):146\u201354. https:\/\/doi.org\/10.1159\/000346602.","journal-title":"Cerebrovasc Dis."},{"key":"852_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000269.pub3","author":"M Fioravanti","year":"2005","unstructured":"Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev. 2005. https:\/\/doi.org\/10.1002\/14651858.CD000269.pub3.","journal-title":"Cochrane Database Syst Rev."},{"issue":"4","key":"852_CR20","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1177\/030006059101900406","volume":"19","author":"R Di Perri","year":"1991","unstructured":"Di Perri R, Coppola G, Ambrosio LA, Grasso A, Puca FM, Rizzo M. A multicentre trial to evaluate the efficacy and tolerability of alpha-glycerylphosphorylcholine versus cytosine diphosphocholine in patients with vascular dementia. J Int Med Res. 1991;19(4):330\u201341. https:\/\/doi.org\/10.1177\/030006059101900406.","journal-title":"J Int Med Res."},{"issue":"5","key":"852_CR21","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0011-393X(05)80518-1","volume":"52","author":"A Muratorio","year":"1992","unstructured":"Muratorio A, Bonuccelli U, Nuti A, Battistini N, Passero S. A neurotropic approach to the treatment of multi-infarct dementia using l-\u03b1-glyceryl-phoshorylcholine. Curr Ther Res. 1992;52(5):741\u201351. https:\/\/doi.org\/10.1016\/S0011-393X(05)80518-1.","journal-title":"Curr Ther Res."},{"issue":"6","key":"852_CR22","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/00002826-199619060-00003","volume":"19","author":"L Pantoni","year":"1996","unstructured":"Pantoni L, Carosi M, Amigoni S, Mascalchi M, Inzitari D. A preliminary open trial with nimodipine in patients with cognitive impairment and leukoaraiosis. Clin Neuropharmacol. 1996;19(6):497\u2013506. https:\/\/doi.org\/10.1097\/00002826-199619060-00003.","journal-title":"Clin Neuropharmacol."},{"issue":"2","key":"852_CR23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/s0022-510x(00)00301-4","volume":"175","author":"L Pantoni","year":"2000","unstructured":"Pantoni L, Bianchi C, Beneke M, Inzitari D, Wallin A, Erkinjuntti T. The Scandinavian multi-infarct dementia trial: a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia. J Neurol Sci. 2000;175(2):116\u201323. https:\/\/doi.org\/10.1016\/s0022-510x(00)00301-4.","journal-title":"J Neurol Sci."},{"issue":"2","key":"852_CR24","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/s0022-510x(00)00300-2","volume":"175","author":"L Pantoni","year":"2000","unstructured":"Pantoni L, Rossi R, Inzitari D, et al. Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian multi-infarct dementia trial. J Neurol Sci. 2000;175(2):124\u201334. https:\/\/doi.org\/10.1016\/s0022-510x(00)00300-2.","journal-title":"J Neurol Sci."},{"issue":"3","key":"852_CR25","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1161\/01.STR.0000155686.73908.3e","volume":"36","author":"L Pantoni","year":"2005","unstructured":"Pantoni L, del Ser T, Soglian AG, et al. Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial. Stroke. 2005;36(3):619\u201324. https:\/\/doi.org\/10.1161\/01.STR.0000155686.73908.3e.","journal-title":"Stroke"},{"issue":"2","key":"852_CR26","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/s0197-4580(00)00225-6","volume":"22","author":"E Farkas","year":"2001","unstructured":"Farkas E, De Jong GI, Apr\u00f3 E, Keuker JI, Luiten PG. Calcium antagonists decrease capillary wall damage in aging hypertensive rat brain. Neurobiol Aging. 2001;22(2):299\u2013309. https:\/\/doi.org\/10.1016\/s0197-4580(00)00225-6.","journal-title":"Neurobiol Aging."},{"issue":"3","key":"852_CR27","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/0047-6374(92)90083-p","volume":"64","author":"GI de Jong","year":"1992","unstructured":"de Jong GI, Traber J, Luiten PG. Formation of cerebrovascular anomalies in the ageing rat is delayed by chronic nimodipine application. Mech Ageing Dev. 1992;64(3):255\u201372. https:\/\/doi.org\/10.1016\/0047-6374(92)90083-p.","journal-title":"Mech Ageing Dev."},{"issue":"10","key":"852_CR28","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1080\/01616412.2017.1356157","volume":"39","author":"M Hu","year":"2017","unstructured":"Hu M, Liu Z, Lv P, et al. Nimodipine activates neuroprotective signaling events and inactivates autophages in the VCID rat hippocampus. Neurol Res. 2017;39(10):904\u20139. https:\/\/doi.org\/10.1080\/01616412.2017.1356157.","journal-title":"Neurol Res."},{"key":"852_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000147","author":"JM L\u00f3pez-Arrieta","year":"2002","unstructured":"L\u00f3pez-Arrieta JM, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev. 2002. https:\/\/doi.org\/10.1002\/14651858.CD000147.","journal-title":"Cochrane Database Syst Rev."},{"issue":"3","key":"852_CR30","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s40520-019-01229-z","volume":"32","author":"E Salvadori","year":"2020","unstructured":"Salvadori E, Poggesi A, Donnini I, et al. Association of nimodipine and choline alphoscerate in the treatment of cognitive impairment in patients with cerebral small vessel disease: study protocol for a randomized placebo-controlled trial-the CONIVaD trial. Aging Clin Exp Res. 2020;32(3):449\u201357. https:\/\/doi.org\/10.1007\/s40520-019-01229-z.","journal-title":"Aging Clin Exp Res."},{"issue":"11","key":"852_CR31","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/wnl.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412\u20134. https:\/\/doi.org\/10.1212\/wnl.43.11.2412-a.","journal-title":"Neurology"},{"issue":"1\u20132","key":"852_CR32","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000081050","volume":"24","author":"L Pantoni","year":"2005","unstructured":"Pantoni L, Basile AM, Pracucci G, et al. Impact of age-related cerebral white matter changes on the transition to disability\u2014the LADIS study: rationale, design and methodology. Neuroepidemiology. 2005;24(1\u20132):51\u201362. https:\/\/doi.org\/10.1159\/000081050.","journal-title":"Neuroepidemiology"},{"issue":"12","key":"852_CR33","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1136\/jnnp.53.12.1080","volume":"53","author":"JC van Swieten","year":"1990","unstructured":"van Swieten JC, Hijdra A, Koudstaal PJ, van Gijn J. Grading white matter lesions on CT and MRI: a simple scale. J Neurol Neurosurg Psychiatry. 1990;53(12):1080\u20133. https:\/\/doi.org\/10.1136\/jnnp.53.12.1080.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"3","key":"852_CR34","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):263\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005.","journal-title":"Alzheimers Dement."},{"key":"852_CR35","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.","edition":"5"},{"issue":"4","key":"852_CR36","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, B\u00e9dirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695\u20139. https:\/\/doi.org\/10.1111\/j.1532-5415.2005.53221.x (Published correction appears in J Am Geriatr Soc. 2019 Sep;67(9):1991).","journal-title":"J Am Geriatr Soc."},{"key":"852_CR37","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1001\/jama.1963.03060120024016","volume":"185","author":"S Katz","year":"1963","unstructured":"Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA. 1963;185:914\u20139. https:\/\/doi.org\/10.1001\/jama.1963.03060120024016.","journal-title":"JAMA"},{"issue":"3","key":"852_CR38","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","volume":"9","author":"MP Lawton","year":"1969","unstructured":"Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179\u201386.","journal-title":"Gerontologist."},{"issue":"5","key":"852_CR39","doi-asserted-by":"publisher","first-page":"471","DOI":"10.5014\/ajot.53.5.471","volume":"53","author":"I G\u00e9linas","year":"1999","unstructured":"G\u00e9linas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer\u2019s disease: the disability assessment for dementia. Am J Occup Ther. 1999;53(5):471\u201381. https:\/\/doi.org\/10.5014\/ajot.53.5.471.","journal-title":"Am J Occup Ther."},{"issue":"11","key":"852_CR40","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1161\/01.str.28.11.2155","volume":"28","author":"A van Straten","year":"1997","unstructured":"van Straten A, de Haan RJ, Limburg M, Schuling J, Bossuyt PM, van den Bos GA. A stroke-adapted 30-item version of the sickness impact profile to assess quality of life (SA-SIP30). Stroke. 1997;28(11):2155\u201361. https:\/\/doi.org\/10.1161\/01.str.28.11.2155.","journal-title":"Stroke"},{"issue":"3","key":"852_CR41","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/014662167700100306","volume":"1","author":"LS Radloff","year":"1977","unstructured":"Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1(3):385\u2013401. https:\/\/doi.org\/10.1177\/014662167700100306.","journal-title":"Appl Psychol Meas"},{"issue":"4","key":"852_CR42","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.3233\/JAD-141449","volume":"43","author":"E Salvadori","year":"2015","unstructured":"Salvadori E, Poggesi A, Pracucci G, Inzitari D, Pantoni L, VMCI-Tuscany Study Group. Development and psychometric properties of a neuropsychological battery for mild cognitive impairment with small vessel disease: the VMCI-Tuscany Study. J Alzheimers Dis. 2015;43(4):1313\u201323. https:\/\/doi.org\/10.3233\/JAD-141449.","journal-title":"J Alzheimers Dis."},{"key":"852_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/9781119413431","volume-title":"Pharmacoepidemiology","author":"BL Strom","year":"2019","unstructured":"Strom BL, Kimmel SE, Hennessy S. Pharmacoepidemiology. New York City: Wiley; 2019."},{"key":"852_CR44","doi-asserted-by":"publisher","first-page":"608013","DOI":"10.1155\/2012\/608013","volume":"2012","author":"A Poggesi","year":"2012","unstructured":"Poggesi A, Salvadori E, Pantoni L, et al. Risk and determinants of dementia in patients with mild cognitive impairment and brain subcortical vascular changes: a study of clinical, neuroimaging, and biological markers-the VMCI-Tuscany Study: rationale, design, and methodology. Int J Alzheimers Dis. 2012;2012:608013. https:\/\/doi.org\/10.1155\/2012\/608013.","journal-title":"Int J Alzheimers Dis."},{"issue":"6","key":"852_CR45","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1159\/000334498","volume":"32","author":"A Poggesi","year":"2011","unstructured":"The LADIS Study Group, Poggesi A, Pantoni L, Inzitari D, et al. 2001\u20132011: a decade of the LADIS (Leukoaraiosis And DISability) study: what have we learned about white matter changes and small-vessel disease? Cerebrovasc Dis. 2011;32(6):577\u201388. https:\/\/doi.org\/10.1159\/000334498.","journal-title":"Cerebrovasc Dis."}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-021-00852-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-021-00852-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-021-00852-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T13:20:37Z","timestamp":1628601637000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-021-00852-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,15]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["852"],"URL":"https:\/\/doi.org\/10.1007\/s40266-021-00852-8","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,15]]},"assertion":[{"value":"28 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Universit\u00e0 degli Studi di Milano within the CRUI-CARE Agreement. MDM Spa Company (Monza, Italy) provided the active drugs and placebo as free donations. The company had no role in the trial\u2019s design or in carrying out the trial, and did not have any role in data analyses.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AP, FP, ID, VR, GC, MS, LT, AM, and FF report no disclosures. LP is a member of the editorial boards of <i>Cerebrovascular Diseases<\/i>, <i>Acta Neurologica Scandinavica<\/i>, <i>Neurological Sciences<\/i>, <i>Cerebral Circulation\u2014Cognition and Behavior<\/i>, and <i>European Stroke Journal<\/i> and a section editor (Vascular Cognitive Impairment) of <i>Stroke<\/i>. ES is a member of the editorial board of <i>Cerebral Circulation\u2014Cognition and Behavior<\/i>.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was performed in accordance with the 1964 Helsinki Declaration and its later amendments and with the ethical standards of the institutional ethics committee, and was approved by the ethics committee of the Careggi University Hospital, Florence, Italy. Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patients signed informed consent regarding publishing their data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Data are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data"}},{"value":"All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by all authors. The first draft of the manuscript was written by LP and ES, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}},{"value":"The authors would like to thank the staff of the Neurology and Geriatric units at the Careggi University Hospital of Florence and the General Medicine physicians for help in referring patients. AP acknowledges Fondazione Cassa di Risparmio di Firenze contribution for local support (Bando Ricerca Scientifica 2017).","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgements"}}]}}